Investor Presentaiton

Key Financials Q4 & FY18 SUN PHARMA Q4 FY18 Q4 FY17 CHANGE FY18 FY17 (All Figures in Rs. Mn) CHANGE Gross Sales 67,110 68,252 -2% 2,60,660 3,02,642 -14% Gross Profit 49,410 46,300 7% 1,86,413 2,21,335 -16% Gross Margin 74% 68% 72% 73% EBITDA 14,174 12,357 15% 51,846 75,394 -31% EBITDA Margin 21% 18% 20% 25% Net Profit 13,090 12,237 7% 21,616 69,644 -69% Net margin 20% 18% 8% 23% Net Profit (Adjusted) 10,504 # 12,237 -14% 33,665 # 69,644 -52% Net margin (Adjusted) 16% 18% 13% 23% R&D 7,428 6,002 24% 22,489 23,138 -3% R&D as % of Net Sales 11.1% 8.8% 8.6% 7.6% EPS (Diluted) INR 5.5 5.1 7% 9.0 29.0 -69% EPS (Diluted) INR (Adjusted) 4.4 # 5.1 -14% 14.0 # 29.0 -52% © Sun Pharmaceutical Industries Limited. All Rights Reserved. # : Adjusted for tax for Q4FY18 includes one-time benefits of Rs. 259 crores related to deferred tax. # : Adjusted for Rs 12.1 bn provision related to Modafinil settlement & deferred tax adjustment for the year FY18 50

View entire presentation